Research & Literature

Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm.

Kei A, Miltiadous G, Bairaktari E, et al.

World journal of clinical cases 2015; (3(4)):371-6 doi:10.12998/wjcc.v3.i4.371.

Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.

Marais D

Current opinion in lipidology 2015; (26(4)):292-7 doi:10.1097/MOL.0000000000000192.

Update on the molecular biology of dyslipidemias.

Ramasamy I

Clinica chimica acta; international journal of clinical chemistry 2016; (454()):143-85.

Type III Hyperlipoproteinemia: Still Worth Considering?

Blum CB

Progress in cardiovascular diseases 2016; (59(2)):119-124 doi:10.1016/j.pcad.2016.07.007.

Postprandial Hyperlipidemia and Remnant Lipoproteins.

Masuda D, Yamashita S

Journal of atherosclerosis and thrombosis 2017; (24(2)):95-109 doi:10.5551/jat.RV16003.

Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.

Koopal C, Marais AD, Visseren FL

Current opinion in endocrinology, diabetes, and obesity 2017; (24(2)):133-139 doi:10.1097/MED.0000000000000316.

Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia.

Bea AM, Civeira F, Jarauta E, et al.

Revista espanola de cardiologia (English ed.) 2017; (70(7)):551-558 doi:10.1016/j.rec.2017.01.023.

Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy.

Koopal C, Marais AD, Westerink J, Visseren FL

Journal of clinical lipidology 2017; (11(1)):12-23.e1 doi:10.1016/j.jacl.2016.10.001.

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Koopal C, Marais AD, Westerink J, et al.

Journal of lipid research 2017; (58(11)):2180-2187 doi:10.1194/jlr.M076901.

The spectrum of type III hyperlipoproteinemia.

Sniderman AD, de Graaf J, Thanassoulis G, et al.

Journal of clinical lipidology 2018; (12(6)):1383-1389 doi:10.1016/j.jacl.2018.09.006.

Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia.

Sniderman AD

Clinical chemistry 2019; (65(2)):225-227 doi:10.1373/clinchem.2018.298026.

Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia.

Boot CS, Middling E, Allen J, Neely RDG

Clinical chemistry 2019; (65(2)):313-320 doi:10.1373/clinchem.2018.292425.

Atypical familial dysbetalipoproteinemia associated with high polygenic cholesterol and triglyceride scores treated with ezetimibe and evolocumab.

Morise AP, Hegele RA

Journal of clinical lipidology 2019; (13(3)):411-414 doi:10.1016/j.jacl.2019.02.006.

Severe Combined Dyslipidemia With a Complex Genetic Basis.

Le R, Abbas M, McIntyre AD, Hegele RA

Journal of investigative medicine high impact case reports 2019; (7()):2324709619877050 doi:10.1177/2324709619877050.

Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.

Sniderman AD, Thanassoulis G, Glavinovic T, et al.

JAMA cardiology 2019; (4(12)):1287-1295 doi:10.1001/jamacardio.2019.3780.

Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia.

Paquette M, Bernard S, Paré G, Baass A

Journal of clinical lipidology 2020; (14(1)):46-52 doi:10.1016/j.jacl.2019.12.006.

The clinical and laboratory investigation of dysbetalipoproteinemia.

Boot CS, Luvai A, Neely RDG

Critical reviews in clinical laboratory sciences 2020; (57(7)):458-469 doi:10.1080/10408363.2020.1745142.

A simplified diagnosis algorithm for dysbetalipoproteinemia.

Paquette M, Bernard S, Blank D, et al.

Journal of clinical lipidology 2020; (14(4)):431-437 doi:10.1016/j.jacl.2020.06.004.

Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm.

Varghese B, Park J, Chew E, et al.

Journal of clinical lipidology 2021; (15(1)):104-115.e9 doi:10.1016/j.jacl.2020.09.011.

Case Report: Hypertriglyceridemia and Premature Atherosclerosis in a Patient With Apolipoprotein E Gene ε2ε1 Genotype.

Limonova AS, Ershova AI, Meshkov AN, et al.

Frontiers in cardiovascular medicine 2020; (7()):585779 doi:10.3389/fcvm.2020.585779.

Adiposity and the development of dyslipidemia in APOE ε2 homozygous subjects: A longitudinal analysis in two population-based cohorts.

Heidemann BE, Wolters FJ, Kavousi M, et al.

Atherosclerosis 2021; (325()):57-62 doi:10.1016/j.atherosclerosis.2021.04.001.

Dysbetalipoproteinemia and other lipid abnormalities related to apo E.

Cenarro A, Bea AM, Gracia-Rubio I, Civeira F

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2021; (33 Suppl 2()):50-55 doi:10.1016/j.arteri.2021.01.002.

Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female.

Seedat F, Patel M, Phillip V, et al.

Clinica chimica acta; international journal of clinical chemistry 2021; (520()):71-75 doi:10.1016/j.cca.2021.05.027.

Role of VLDL receptor in atherogenesis.

Takahashi S

Current opinion in lipidology 2021; (32(4)):219-225 doi:10.1097/MOL.0000000000000760.

Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?

Higgins V, Leiter LA, Delaney SR, Beriault DR

Clinical biochemistry 2022; (99()):60-68 doi:10.1016/j.clinbiochem.2021.10.003.

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).

Waldmann E, Wu L, Busygina K, et al.

PloS one 2022; (17(3)):e0265838 doi:10.1371/journal.pone.0265838.

Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

Heidemann BE, Koopal C, Baass A, et al.

Clinical genetics 2022; (102(4)):253-261 doi:10.1111/cge.14185.

Palmar Striated Xanthomas in Clinical Practice.

Roy N, Gaudet D, Brisson D

Journal of the Endocrine Society 2022; (6(8)):bvac103 doi:10.1210/jendso/bvac103.

Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol.

Sampson M, Wolska A, Meeusen JW, et al.

Frontiers in genetics 2022; (13()):935257 doi:10.3389/fgene.2022.935257.

Role of Lipid-Lowering Therapy in Peripheral Artery Disease.

Belur AD, Shah AJ, Virani SS, et al.

Journal of clinical medicine 2022; (11(16)) doi:10.3390/jcm11164872.

Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management.

Barclay K, Koysombat K, Padmagirison R, Kaplan F

BMJ case reports 2022; (15(8)) doi:10.1136/bcr-2022-249000.

Dysbetalipoproteinemia Is Associated With Increased Risk of Coronary and Peripheral Vascular Disease.

Paquette M, Bernard S, Baass A

The Journal of clinical endocrinology and metabolism 2022; (108(1)):184-190 doi:10.1210/clinem/dgac503.

Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia.

Heidemann BE, Koopal C, Roeters van Lennep JE, et al.

Journal of clinical lipidology 2023; (17(1)):112-123 doi:10.1016/j.jacl.2022.10.006.

Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol measurement in Familial Dysbetalipoproteinemia.

Heidemann BE, Koopal C, Roeters van Lennep JE, et al.

Clinica chimica acta; international journal of clinical chemistry 2023; (539()):114-121 doi:10.1016/j.cca.2022.11.035.

Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype.

Bea AM, Cenarro A, Marco-Bened V, et al.

Clinical chemistry 2023; (69(2)):140-148 doi:10.1093/clinchem/hvac213.

Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.

Yanai H, Adachi H, Hakoshima M, Katsuyama H

International journal of molecular sciences 2023; (24(18)) doi:10.3390/ijms241813942.

Prevalence of Dysbetalipoproteinemia in the UK Biobank According to Different Diagnostic Criteria.

Paquette M, Trinder M, Guay SP, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(3)):e703-e709 doi:10.1210/clinem/dgae259.

Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.

Guo JL, Braun D, Fitzgerald GA, et al.

Cell 2025; (188(1)):187-206.e26 doi:10.1016/j.cell.2024.10.027.

Clinical and biochemical features of atherogenic hyperlipidemias with different genetic basis: A comprehensive comparative study.

Blokhina AV, Ershova AI, Kiseleva AV, et al.

PloS one 2024; (19(12)):e0315693 doi:10.1371/journal.pone.0315693.

Multidisciplinary teams in clinical lipidology and cardiometabolic care: A National Lipid Association Expert Clinical Review.

Cheeley MK, Kirkpatrick CF, Brown EE, et al.

Journal of clinical lipidology 2025; (19(4)):737-747 doi:10.1016/j.jacl.2025.05.002.

Research advances in current drugs targeting hyperlipidemia (Review).

Zhao H, Wang Y, Li Y, et al.

Molecular medicine reports 2025; (32(4)).

Genetic and Metabolic Factors of Familial Dysbetalipoproteinemia Phenotype: Insights from a Cross-Sectional Study.

Blokhina AV, Ershova AI, Kiseleva AV, et al.

International journal of molecular sciences 2025; (26(15)) doi:10.3390/ijms26157376.